## AGGEVED CENTRAL PAX CENTER

APR 1 1 2007



Vertex Pharmaceuticals Incorporated
130 Waverly Street • Cambridge, MA 02139-4242
Tel. 617.444.6100 • Fax 617.444.6483
http://www.vitx.com

# **FAX TRANSMISSION**

То	USPTO
	Mail Stop Amendment
Examiner	Joseph R. Kosack
Group Art Unit	1626
From	Daniel A. Pearson
Date	April 11, 2007
Application No.	10/798,766
Attorney Docket No.	VPI/03-101
Total Pages	:30

### **Message or Comment**

If any problems occur with this fax transmittal, please call (617) 444-7517 immediately.

### RECEIVED CENTRAL FAX CENTER

### APR 1 1 2007

Attorney Docket No.: VPI/03-101 US

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/798,766

Confirmation No.:

8361

Filing Date:

March 11, 2004

Examiner:

Joseph R. Kosack

Group Art Unit:

1626

Applicants:

Francois Maltais

For:

COMPOSITIONS USEFUL AS PROTEIN KINASE

**INHIBITORS** 

#### Certificate of Facsimile Transmission Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto are being facsimile transmitted to the United States Patent and Trademark Office on April 11, 2007.

April 11, 2007

Cambridge, Massachusetts

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Reply to Office Action; [] a Terminal Disclaimer Under 37 C.F.R. § 1.321(b) and (c); [] a Declaration; [] a Power of Attorney; [] a copy of a Notice to File Missing Parts; [] a Response to Notice to File Missing Parts; [] a Supplemental Declaration; [] an Associate Power of Attorney; [] a substitute Specification; [] formal drawings; [] Notice of Appeal; [] Appeal Brief; [] Petition for Revival; to be filed in the above-identified patent application.

Applicants:

François Maltais et al.

Application No.:

10/798, 766

### FEE FOR ADDITIONAL CLAIMS

[X] A fee for additional claims is not required.

[] A fee for additional claims is required.

The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUS PAID FOR	SLY	PRESENT EXTRA	RATE		ADDITION FEES	NAL
TOTAL	CLAIMS	•	* =	,X	\$ 50	=	\$	0
INDEPI CLAIM	ENDENT S	<u>.</u>	்≉ ≉ . ≃	х	\$200	=	\$	0
	PRESENTATION O PLE DEPENDENT		-	+ .	\$360	=	\$	
	If less than 20, insert If less than 3, insert 3			TOTAL			\$	0
•	17 A abaals to the			. 64	-1· c		•44 1	

- [] A check in the amount of \$\_\_ in payment of the filing fee is transmitted herewith.
- [] Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- [X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Applicants:

François Maltais et al.

Application No.:

10/798, 766

N	<b>AIS</b>	CEL	LAN	EO	US	<b>FEES</b>
---	------------	-----	-----	----	----	-------------

1	Please charge \$	to Deposit Account No. 50	1-0725 in payment of the
	for	(37 C.F.R. §	).

Flespectfully submitted

Daniel A. Pearson, Reg. No. 58,053
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6790
Fax: (617) 444-6483